Lung cancer screening with computerised tomography holds promise, but optimising the balance of benefits and harms via selection of a high risk population is critical. PLCO m2012 is a logistic regression model based on U.S. data, incorporating sociodemographic and health factors, which predicts 6-year lung cancer risk among ever-smokers, and thus may better predict those who might benefit from screening than criteria based solely on age and smoking history. We aimed to validate the performance of PLCO m2012 in predicting lung cancer outcomes in a cohort of Australian smokers. Predicted risk of lung cancer was calculated using PLCO m2012 applied to baseline data from 95,882 ever-smokers aged 45 years in the 45 and Up Study (2006)(2007)(2008)(2009). Predictions were compared to lung cancer outcomes captured to June 2014 via linkage to population-wide health databases; a total of 1,035 subsequent lung cancer diagnoses were identified. PLCO m2012 had good discrimination (area under the receiver-operating-characteristic-curve; AUC 0.80, 95%CI 0.78-0.81) and excellent calibration (mean and 90th percentiles of absolute risk difference between observed and predicted outcomes: 0.006 and 0.016, respectively). Sensitivity (69.4%, 95%CI, 65.6-73.0%) of the PLCO m2012 criteria in the 55-74 year age group for predicting lung cancers was greater than that using criteria based on 30 pack-years smoking and 15 years quit (57.3%, 53.3-61.3%; p < 0.0001), but specificity was lower (72. 0%, 71.7-72.4% versus 75.2%, 74.8-75.6%, respectively; p < 0.0001). Targeting high risk people for lung cancer screening using PLCO m2012 might improve the balance of benefits versus harms, and cost-effectiveness of lung cancer screening.
Lung cancer screening with computerised tomography holds promise, but optimising the balance of benefits and harms via selection of a high risk population is critical. PLCO m2012 is a logistic regression model based on U.S. data, incorporating sociodemographic and health factors, which predicts 6-year lung cancer risk among ever-smokers, and thus may better predict those who might benefit from screening than criteria based solely on age and smoking history. We aimed to validate the performance of PLCO m2012 in predicting lung cancer outcomes in a cohort of Australian smokers. Predicted risk of lung cancer was calculated using PLCO m2012 applied to baseline data from 95,882 ever-smokers aged 45 years in the 45 and Up Study (2006) (2007) (2008) (2009) . Predictions were compared to lung cancer outcomes captured to June 2014 via linkage to population-wide health databases; a total of 1,035 subsequent lung cancer diagnoses were identified. PLCO m2012 had good discrimination (area under the receiver-operating-characteristic-curve; AUC 0.80, 95%CI 0.78-0.81) and excellent calibration (mean and 90th percentiles of absolute risk difference between observed and predicted outcomes: 0.006 and 0.016, respectively). Sensitivity (69.4%, 95%CI, 65.6-73.0%) of the PLCO m2012 criteria in the 55-74 year age group for predicting lung cancers was greater than that using criteria based on 30 pack-years smoking and 15 years quit (57.3%, 53.3-61.3%; p < 0.0001), but specificity was lower (72.0%, 71.7-72.4% versus 75.2%, 74.8-75.6%, respectively; p < 0.0001). Targeting high risk people for lung cancer screening using PLCO m2012 might improve the balance of benefits versus harms, and cost-effectiveness of lung cancer screening.
Lung cancer is the leading cause of cancer-related death worldwide. 1 Potentially screen-detectable, non-small cell lung cancers account for around 85% of all lung cancers, and survival for these cancers can be improved if detected and treated at an early stage. 2, 3 In 2011, a 20% (95% CI 6.8% 226.7%) relative reduction in mortality from lung cancer was observed among long-term, heavy smokers screened with low dose computed tomography (LDCT) in the National Lung Cancer Screening Trial (NLST) after three rounds of annual screening. 4 As a consequence, several organisations are now recommending annual lung screening with LDCT in line with the NLST eligibility criteria, that is, those aged 55-74 years with 30 pack-years smoking history and who have quit within the past 15 years. [5] [6] [7] [8] [9] Based on modelled analysis, 10 the United States Preventive Services Task Force recommended extending the age of annual screening up to age 80 years in this group.
have been reported inconsistently across studies making comparison difficult. 15 However, during the screening phase of the NLST, 39.1% of LDCT group participants had at least one positive screening result, equating to 24.2% of all LDCT scans undertaken. 4 Of these positive scans, 96.4% were false positives. Across an entire screened population, the risk of death and major complications following diagnostic events for benign nodules is estimated via systematic review of the literature to be 4.1 and 4.5 per 10,000, respectively. 15 In countries outside the United States, lung cancer screening has not been systematically introduced, in part because many questions remain with regard to translating trial findings into clinical practice at a population level, including optimising the target population. 5 Highlighting the importance of these research gaps, two European LDCT lung screening trials with differing eligibility criteria have produced inconclusive results, 16, 17 and has led to speculation that patient selection is critical to screening effectiveness. 17, 18 Lung cancer screening has only been shown to reduce lung cancer mortality for individuals at highest risk of lung cancer. 12, 19 The target population for lung screening in the NLST was primarily defined by age and smoking history but there is potential to optimise the target screening group further by utilising risk prediction tools. The PLCO m2012 is a logistic regression lung cancer risk prediction model which was designed using 6-year incidence data for lung cancer occurring in smokers in the control arm of the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial (PLCO; 1993-2001). The model was originally validated using data from PLCO intervention arm smokers and the NLST [20] [21] [22] and in a recent independent validation exercise, it was found to have had high predictive performance in the German-EPIC cohort. 23 PLCO m2012 incorporates smoking intensity, duration and years quit as separate continuous variables as well as additional demographic and health-related factors. Individuals are stratified into high and low risk groups using a threshold risk of 1.51% for developing lung cancer over 6 years, because this level of risk yielded a mortality benefit for LDCT screening in the NLST. 22 Using PLCO m2012 1.51%
would reduce the number needed to screen to prevent one lung cancer death from 320 to 255 and has been suggested as an alternative screening eligibility threshold. 22 The overall objective of this investigation was to obtain data on the likely applicability of PLCO m2012 to the Australian population, using a large-scale population-based cohort of people aged 45 years.
Material and Methods

Study population
The Sax Institute's 45 and Up Study is an Australian cohort study of 267,019 men and women aged 45 and over resident in New South Wales (NSW), Australia, randomly sampled from the Medicare enrolment database (which includes all citizens and permanent residents of Australia; the sample is estimated at 11% of the population in this age group). Individuals joined the study by completing a postal questionnaire (distributed 2006-2009) and giving informed consent for linkage of their data to population health databases. People aged over 80 years and those living in regional and remote areas were oversampled by a factor of two. The study methods and a characterisation of the cohort are described in detail elsewhere, 24, 25 as are the health and social characteristics of smokers compared to non-smokers within the cohort. [25] [26] [27] [28] [29] Baseline questionnaire data included information on socio-demographic factors, health behaviours and medical history.
Ethics approval for the 45 and Up Study as a whole was provided by the University of NSW Human Research Ethics Committee and specifically for this analysis by the NSW Population and Health Services Research Ethics Committee.
Data sources and probabilistic record linkage
Questionnaire data from study participants were linked probabilistically to a number of population-wide health databases: (1) the NSW Admitted Patient Data Collection (APDC; Jul 2001-Jun 2014), which is a complete census of all public and private hospital admissions in NSW; (2) the NSW Cancer Registry (NSWCR; Jan 1994-Dec 2010), which receives all notifications of cancer for residents of NSW; and (3) the Register of Births, Deaths and Marriages (RBDM; Jan 2006-Dec 2014), which contains all death notifications. These datasets were linked by the Centre for Health Record Linkage 30 using a best practice approach in privacy-preserving record linkage 31 and the open source probabilistic record linkage software ChoiceMaker. The probabilistic matching process is known to be highly accurate (false-positive and false-negative rates <0.5%) and a more detailed description of the linkage process has been reported previously. 32 Medication use and All risk factors required for the PLCO m2012 algorithm, except history of chronic obstructive pulmonary disease (COPD), were self-reported in the 45 and Up Study baseline questionnaire. These were: smoking status (current/past), smoking intensity (number of cigarettes/day), smoking duration (number of years smoked), number of years quit for exsmokers, education (in 6 levels that were defined slightly differently to the 6 levels in PLCO m2012 ), ethnicity (defined by country of birth: Asian, Pacific Islander, all others combined), body mass index (BMI; calculated from self-reported height and weight), personal history of cancer and family history of lung cancer. Pack-years was calculated by multiplying the number of years smoked by the number of packs smoked per day, assuming a pack contained 20 cigarettes. History of COPD at baseline was ascertained from APDC records (2001-cohort entry date) where diagnosis codes for bronchitis, chronic bronchitis, emphysema and other COPD (i.e., ICD10-AM J40-J44) were present, and from PBS records (2005-cohort entry date) where a prescription for tiotropium bromide monohydrate and/or ipratropium bromide was filled.
Statistical methods
This analysis was restricted to 95,882 current and former smokers aged 45 years and over at cohort entry, with complete information on all self-reported PLCO m2012 risk factors and at least 5 years of follow up (35.9% of original cohort). Exclusions comprised 18,004 ever smokers with missing data for 1 or more risk factors, 549 with a prior history of lung cancer and 34 participants recruited after 30th June 2009.
Data were censored at death, date of lung cancer diagnosis, at 6 years of follow-up, or at 30 June 2014, whichever came first. Although based on a logistic regression model, PLCO m2012 was shown to have similar effect estimates (hazard ratios and odds ratios), standard errors and predictive performance when the same predictors were used in a Cox survival model. 21 Given the cohort design of our study, we used age-and sex-adjusted Cox proportional hazard regression models to describe the relative risk and 95% confidence intervals of lung cancer incidence for each of the PLCO m2012 risk factors in the sample. PLCO m2012 risk scores were calculated according to the published algorithm. 21 The PLCO m2012 was designed to estimate 6-year lung cancer risk, however some participants had between 5 and 6 years follow-up at the time of analysis. In sensitivity analyses, we compared the predictive performance of the PLCO m2012 for 5 versus 6 years of follow-up, and also assessed the effects of the method of case ascertainment by using only APDC-identified cases. Although APDC case ascertainment is not considered 'gold standard', the purpose of using only APDC-identified cases in sensitivity analysis was to determine whether and how much the model underperformed using the less complete dataset of cases.
The discriminatory power of the PLCO m2012 was assessed by the area under the receiver-operator-characteristic (ROC) curve (AUC). The AUC plots the true-positive proportion (sensitivity) versus false-positive proportion (1-specificity). ROCs were generated from logistic regression models with 95% Wald confidence intervals for the AUC. Calibration was assessed by plotting the observed probabilities versus modelpredicted probabilities when pooled into groups by decile of model-predicted risk. The absolute difference between predicted and observed probabilities was calculated for each decile of risk score. The mean and 90th percentiles of absolute difference between model-predicted probability and observed probability were calculated. Calibration was also assessed by a Brier score, which is the average of the squared difference between the observed and predicted risks. A lower Brier score indicates better prediction, and a Brier score of 0.25 represents random classification.
The clinical utility of the models was evaluated using various risk thresholds by comparing the proportion of participants who did and did not develop cancer depending on their PLCO m2012 risk calculation. Classification was assessed by sensitivity, specificity and positive and negative predictive value (PPV/NPV) and 95% confidence intervals were calculated for sensitivity and specificity assuming a binomial distribution. Statistical differences in the sensitivity and specificity of different risk thresholds were assessed using McNemar's test among those with and without lung cancer, respectively. 34 We ascertained the risk threshold at which sensitivity and specificity were optimal in the cohort across varying age ranges. The optimal balance between sensitivity and specificity was calculated by finding the point on the ROC curve nearest to 0, 1 (perfect classification). The optimal threshold was then compared against other high risk criteria classifications: (1) PLCO m2012 0.0151, which was the risk score at which a mortality benefit of computed tomography (CT) screening versus chest X-ray was observed in the NLST trial 22 ; (2) the NLST and USPSTF high risk criteria, which are 30 pack-years of cigarette smoking history and 15 years since quitting for former smokers among those aged 55-74 and 55-80 years, respectively; (3) PLCO m2012 risk 0.02, with the purpose of illustrating the effects of a more conservative threshold. We also compared the relative utility of the 0.0151 risk threshold across different age ranges, as well as when each factor was individually omitted from the model.
Analyses were performed in SAS version 9.4 (SAS Institute Inc, Cary, NC) and STATA release 12 (StataCorp,College Station, TX).
Results
In the 5-6 year follow-up period, 1,035 incident lung cancer diagnoses and 7,392 deaths from all causes were observed. Among participants with 6 years of follow-up (n 5 44,236, 46.1%), 519 incident lung cancers and 3,768 deaths occurred. Among participants with 5-5.9 years of follow-up (n 5 51,648, 53.9%; median 5.8 years; quartile 1 and 3 (Q1-Q3) 5.7-5.9), 516 lung cancers and 3,624 deaths occurred. The distribution of lung cancers by method of case ascertainment is presented in Supporting Information Table 1 .
Overall, 16.8% of the analysis sample were current smokers at baseline (Table 1) , and mean number of years quit among ex-smokers was 22.4 (standard deviation; SD, 12.8). Current smokers reported a mean of 47.1 (SD, 33.1) and exsmokers a mean of 24.7 (SD, 23.6) pack-years. The distribution of PLCO m2012 predictor variables, as well as sex, at baseline by lung cancer status is presented in Table 1 . Lung cancer incidence varied significantly with each risk factor except sex, ethnicity and BMI. Participants with lung cancer had smoked a median of 41 pack-years and ex-smokers with lung cancer had quit a median of 16 years prior to baseline. COPD was identified in 6.6% of the analysis sample at baseline and was largely identified via those who had filled a prescription for tiotropium and/or ipratropium bromide between 2005 and cohort entry (see Supporting Information T2). The prevalence of COPD in the entire cohort (see Supporting Information T3), was similar to that reported for Australia in 2011-2012. 35 Predictive performance of the PLCO m2012 PLCO m2012 risk scores ranged from 0 to 0.866 (median, 0.005; Q1-Q3 0.002-0.0151) and were higher for men (median, 0.007; Q1-Q3 0.002-0.019) than women (median, 0.003; Q1-Q3 0.0009-0.011). The PLCO m2012 model had high discrimination, with an AUC of 0.80 (95% CI, 0.78-0.81) (ROC curve: Supporting Information Figure 1 ) and excellent calibration with mean and 90th percentile absolute difference between observed and predicted probabilities of 0.006 and 0.016, respectively and a Brier score of 0.01 (Fig. 1) . Discrimination remained high when the analysis was limited to men (AUC 0.80, 95% CI 0.78-0.81), women (AUC 0.79, 95% 0.77-0.82) and participants in the NLST eligible age range (55-74 years; AUC 0.78, 95% CI 0.76-0.80).
Evaluation of PLCO m2012 risk thresholds compared to NLST and USPSTF risk criteria
The sensitivity, specificity, positive and negative predictive value of various PLCO m2012 model thresholds are presented in Table 2 and compared to the NLST and USPSTF risk criteria. The thresholds that were closest on the ROC curve to perfect classification were 0.0113 for the whole sample and 0.0149 for those aged 55-74 years (i.e., very close to PLCO m2012 0.0151 threshold). When the sample was restricted to the NLST eligible age range 55-74 years, the PLCO m2012 0.0151 threshold resulted in higher sensitivity than the NLST criteria (69.4% versus 57.3%; p < 0.0001), but lower specificity (72.0% versus 75.2%; p < 0.0001), and a higher proportion of participants were criteria positive (28.5% versus 25.2%). When the threshold was adjusted to match the number of criteria positive participants according to the NLST eligibility criteria (i.e., 25.2%), both sensitivity and specificity were higher using the PLCO m2012 0.0151 threshold. Similarly, compared to the USPSTF criteria (i.e., 55-79 years), the PLCO m2012 0.0151 threshold had higher sensitivity but lower specificity (both p < 0.0001). When we tested the more conservative 0.02 (2%) PLCO m2012 threshold, the tool performed better than the NLST with superior sensitivity (p 5 0.002) and specificity (p < 0.0001), and had higher sensitivity than the USPSTF risk criteria (p < 0.0001) with no loss in specificity (p 5 0.39). When the density of risk was plotted for those with versus without lung cancer (Fig. 2) , the 0.0151 PLCO m2012 threshold crossed the intersection point of the curves (lung cancer versus no lung cancer), where the density of risk for ages 55-74 years is greater among those with lung cancer than those without.
Predictive performance of PLCO m2012 by age A comparison of the predictive performance of the 0.0151 PLCO m2012 threshold for different age ranges is presented in Table 3 . Mean PLCO m2012 risk, and accordingly, the proportion of participants who are criteria positive increased with age. The trade-off between specificity and sensitivity changed with age. Specificity was highest in the 45-54-year age group but this group had a high false negative rate (81.7%). Sensitivity was highest for the 75-79-year age group but those in the 75-79 and 801 year age groups had high false positive rates (53.6% and 56.6%, respectively). (The distribution of lung cancer cases by age and density of risk is plotted in Supporting Information Figure 2. ) Impact of each model factor on predictive performance of PLCO m2012
Individually eliminating either education, ethnicity, BMI, COPD, a previous cancer diagnosis, or family history of cancer from the PLCO m2012 risk calculation for 55-74-year olds had no material effect on the predictive performance of the model in this validation dataset (Table 4) . Omitting smoking intensity, duration, and number of years quit had the largest effects on predictive outcomes. When risk was calculated using only age and smoking-specific risk factors, the false negative rate was greater than that observed for the full model at the 0.0151 threshold; however, it still performed better overall than the NLST eligibility criteria, with 11.6% of participants positive by one criterion but not the other (see Supporting Information T4). Furthermore, using only smoking and age criteria, more than a third of lung cancer cases were missed by both criteria. Sensitivity analyses demonstrated that there were no material differences in calibration and discrimination when the sample was restricted to those with <6 years follow-up (i.e., those recruited to the cohort later; AUC 0.81, 95% CI 0.80-0.83). Differences in predictive performance by length of follow-up were unlikely to be due to the method of case ascertainment; when all cases were ascertained by APDC records alone, discrimination and calibration were almost identical to that observed with the model using NSWCR cases to 2010 and supplemented by the APDC to 2014 (AUC 0.80, 95% CI 0.78-0.81) (see Supporting Information Figure 3 ).
Discussion
We found that the PLCO m2012 lung cancer risk assessment tool, which was developed in a population of screening trial participants in the United States, had high predictive performance when applied to a large population-based cohort in Australia, with both excellent discrimination and calibration. The PLCO m2012 risk threshold of 0.0151 was that for which a mortality benefit of CT screening versus chest X-ray was observed in the NLST trial. 22 When applied to the 45 and Up Study data, this threshold coincided with the point at which density of risk became greater among those who were diagnosed with lung cancer within 6 years than those who did not, which provides independent validation for using the PLCO m2012 0.0151 threshold for identifying those at high risk. Similar to previous reports, PLCO m2012 risk 0.0151 yielded a higher positive predictive value and sensitivity than the NLST eligibility criteria for identifying lung cancer cases, with minimal loss in specificity. 21, 22 The tool appeared to perform best among participants aged 55-74 years, with the threshold of 0.0151 coinciding with the value on the ROC curve closest to perfect classification. This finding aligns with the fact that the PLCO m2012 tool was developed and validated on participants in the 55-74-year age range. 
Cancer Epidemiology
As expected, the PLCO m2012 tool appeared to be largely driven by the two primary risk factors for lung cancer: smoking history and age. This result explains the robustness of the PLCO m2012 tool for predicting lung cancer across populations with potentially different risk profiles. Furthermore, we demonstrated that if the only information available to predict 6-year lung cancer risk was age, smoking duration, intensity and years quit, the PLCO m2012 model would still be better at 
Weber et al. identifying high risk individuals aged 55-74 years than the more categorical, dichotomised NLST criteria. Ethnicity and education were two factors in our sample that did not completely align with the original model. The ethnicity profile in this Australia population differs from that in the setting the tool was originally designed, and the classification of educational attainment also differed slightly in the two settings. This suggests that predictive performance could potentially be improved if the model was adjusted to reflect ethnic variation in lung cancer incidence in Australia rather than in the United States. However, eliminating any one of the demographic or health-related factors from the model resulted in no loss of discrimination and only minor variation in sensitivity and specificity at the 0.0151 threshold. Similarly, PLCO m2012 also had high predictive performance in a German population despite baseline information on COPD being unavailable. 23 Removing COPD from the model in our study was associated with a slight decrease in the number criteria positive at PLCO m2012 0.0151 and a marginal increase in the false negative rate (from 26.9% to 27.9%). Case ascertainment for the presence of COPD included PBS prescriptions for inhaled antimuscarinic agonists. Whilst these medicines are first line treatment for breathlessness in COPD we cannot exclude the possibility that these may have been prescribed for severe asthma, which may have diluted the numbers of true COPD cases. However, the prevalence of COPD in the entire cohort was similar to national estimates for Australia 35 and the presence of COPD in our cohort conferred a 3.5 fold increased hazard ratio for lung cancer, demonstrating an important effect. Furthermore, a recent post-hoc analysis of the NLST found that COPD may be a key factor in reducing the rate of overdiagnosis within a LDCT screening population. 36 Thus, although the current evidence supports potential use of the more parsimonious model, slight benefits of the full model cannot be excluded and could become more relevant when applied at the population level.
Application of risk prediction models, like PLCO m2012 to lung cancer screening has the capacity to save additional lives, reduce the number of false positives and make screening more efficient and cost-effective. 37 There is a pressing need for evidence on the harms and benefits of lung cancer screening, especially outside of North America, where trial data are limited. For example, the Australian government released an updated position statement in 2015 recommending that a national approach to lung cancer screening not be implemented until further evidence accrues. 38 The USPSTF recommends screening up to age 80 years with the same smoking criteria as the NLST. 11 In our cohort, the PLCO m2012 was more sensitive for identifying lung cancer cases than the USPSTF risk criteria. Our data demonstrate that the median time to lung cancer diagnosis since quitting in ex-smokers was 16 years, suggesting that the USPSTF cut off of 15 years since quitting may not identify a large proportion of high risk individuals in our cohort, and thus lead to lower performance. When we assessed the PLCO m2012 tool on participants aged 75-79 years, sensitivity and PPV were high at the 0.0151 threshold, but over half were criteria positive, and specificity was only 46.4%. Indeed, as age increased, a greater proportion of participants were criteria positive by the PLCO m2012 0.0151 threshold, thereby increasing sensitivity but decreasing specificity. When a PLCO m2012 0.02 threshold was applied, the tool performed better than the USPSTF risk criteria, with higher sensitivity and no loss in specificity. Consideration for the trade-off between sensitivity and specificity is needed when considering older age ranges.
Among ages younger than 55 years (45-54) only a small proportion went on to develop lung cancer within 6 years, and 87% of the lung cancers diagnosed had PLCO m2012 risk values that were lower than the 0.0151 threshold. Because the PLCO m2012 tool was designed for people aged 55-74 years, it is possible that the relative contribution of each risk factor to the PLCO m2012 model is different for ages outside the 55-74 year age range, and that tools specific for older ages might be more appropriate. On the basis of our results, lung screening for individuals targeted by the PLCO m2012 tool would not be recommended for ages 45-54 years. Furthermore, for those under 50 years, the harm caused by excessive radiation and resultant cancer deaths may preclude LDCT lung cancer screening. For them the lung cancer risk needs to be very high and the model needs to be very accurate, if screening is at all to be considered. 39 Determining the optimal age range for screening requires evaluation of factors in addition to predictive performance, including and not limited to, the number needed to screen to prevent a lung cancer death, the balance of benefits and harms involved in the follow-up of false positives, quality of life and overall cost effectiveness. Our findings will feed into specific modelling of cost effectiveness and benefits versus harms of these extended age options for screening. The PLCO m2012 0.0151 threshold occurred at the 71st percentile among those aged 55-74 years in our cohort. On the basis of this result, we could estimate that roughly 29% of ever smokers in Australia aged 55-74 years would be eligible for screening using the PLCO m2012 0.0151 criteria. In 2013 in Australia, there were 4.9m current or former smokers between the ages of 50 and 70 years, 40, 41 indicating that as many as 0.7m people may be eligible for screening at the PLCO m2012 0.0151 threshold, or 0.5m at the 0.02 threshold. These estimates are slightly higher than those reported in the Busselton Health Study for ages 55-68 years in Australia (17.9-20.0% criteria positive at PLCO m2012 0.0151 versus 23.9% for this age range in our study, data not shown). 42 The conflicting estimates derived from these studies highlight the need for caution when generalising from cohort studies of these types to inform prevalence estimates for the population as a whole. That is, the varying estimates may reflect differences in study participation rates, the potential for selection bias, and possible differences in the underlying population of smokers from which the studies were sampled. Interpretation of our results should be considered in light of a number of limitations. First, we used different sources of case ascertainment across the study period (i.e., NSWCR up to 2010, and APDC 2011-2014), which meant that model performance for participants who entered the study later on in the 2006-2009 recruitment period may have been underestimated. The APDC captures cases that were hospitalised due to lung cancer treatment and/or complications, and would not capture those participants who may have died without hospitalisation due to reasons such as advanced stage of disease at diagnosis, or those who may have been treated outside of NSW, the state where the study took place. Indeed, a validation study on the use of APDC for capturing lung cancer cases in the 45 and Up Study demonstrated that, of those cases that were record in the NSWCR to 2010 that were missing from the APDC, around half were from areas near the border of another state or territory, so they might have been hospitalised interstate. 33 Missed cases were also more likely to have unknown spread of disease at diagnosis suggesting they died without treatment, were more commonly from non-metropolitan and lower socioeconomic areas, and were slightly older. 33 Second, model performance may also have been underestimated for participants who entered the study later because they had <6 years of follow-up at the time of analysis, and the PLCO m2012 was designed to estimate risk within 6 years. The impact of a shorter follow-up period, with potentially fewer cases than would have been observed with the full 6 years, would mean that the PLCO m2012 may have slightly under-performed in our analysis.
Due to possible selection bias, our cohort is likely to have reduced representation of population groups who have more extreme health behaviours and higher smoking rates, such as those who are mentally or physically ill, or marginalised for some other reason. Furthermore, the survival bias inherent in cohort studies of older age groups and especially samples of long-term smokers, mean that an estimate of 29% eligible is likely to be conservative. Conversely, the heaviest smokers in the population are those most likely to have multiple, or serious comorbidities, putting them in a subgroup for which screening may be inappropriate. Specifically, only those with both reasonable life expectancies and suitability for lung cancer treatment will benefit from screening. Taking all these factors into account, the prevalence estimate from this cohort is likely to represent a somewhat conservative, but justifiable, approximation of the number of individuals who would be eligible for screening in the population as a whole. Nevertheless, refining estimates of the number eligible for screening in Australia, taking into account historical smoking rates over time and competing causes of death and disability is the subject of future research.
This study provides the largest independent validation of the PLCO m2012 tool for predicting lung cancer outcomes outside the U.S. population and has major implications for improving the trade-off between the harms and benefits of lung cancer screening by better targeting high risk individuals, and consequently its cost-effectiveness. A number of screening trials using the PLCO m2012 to define eligibility are underway and will go some way to addressing issues around implementation, such as: administering the tool in a clinical setting, strategies around communicating risk to individuals, incorporation of smoking cessation strategies, issues of screening discontinuation (given the USPSTF recommendation that screening cease once an individual has not smoked for 15 years), protocols for lung nodule management and optimal treatment pathways.
